ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting

SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting. The biomarker demonstrated the ability to predict the benefit of long-term androgen deprivation…